LifeSenze WELLMENZ Tablet
LifeSenze WELLMENZ Tablet : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
- Conditions légales
Lepidium meyenii Walp.: L'absence d'alcaloïdes doit être démontrée par des rapports d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| Withania somnifera | Withania somnifera[337.5 mg,1365 mg] | Not identified |
| Beta vulgaris | Beta vulgaris[180 mg,1365 mg] | Not identified |
| Serenoa repens | Serenoa repens[100 mg,1365 mg] | Not identified |
| Eurycoma longifolia | Eurycoma longifolia[45 mg,1365 mg] | Not identified |
| Lepidium meyenii | Lepidium meyenii[45 mg,1365 mg] | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- MAL24066105TC
- Type
- Natural product
- Published status
- PRODUCT APPROVED
- Licence holder
- HL PHARMACEUTICALS SDN. BHD.
- Manufacturer
- YANLING NATURAL HYGIENE SDN. BHD.
- Registration period starting
- 2024-06-10
- Published validity end
- 2029-06-10
Original register data
View published fields and their variants
- Active ingredients
- Withania somnifera[337.5 mg,1365 mg],Beta vulgaris[180 mg,1365 mg],Serenoa repens[100 mg,1365 mg],Eurycoma longifolia[45 mg,1365 mg],Lepidium meyenii[45 mg,1365 mg]
- Valid until
- 2029-06-10
- Registration date
- 2024-06-10
- Published description
- NATURAL PRODUCT
- Licence holder
- HL PHARMACEUTICALS SDN. BHD.
- Producer
- YANLING NATURAL HYGIENE SDN. BHD.
- Published name
- LifeSenze WELLMENZ Tablet
- Published reference
- 2024020514005T
- Registration number
- MAL24066105TC
- Published status
- PRODUCT APPROVED
Official source
View the official register, number MAL24066105TC
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Withania somnifera
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Sources cited by Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Serenoa repens
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
- Lepidium meyenii
Read the warning, when it applies and the studies cited
Maca - Lepidium Meyenii
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Applies to products providing 0.6 g or more dried root/hypocotyl, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).
Sources cited by Health Canada (1)
- Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Sources cited by Health Canada (2)
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
Condition of application: Healthy mood balance; Sexual health.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Sources cited by Health Canada (3)
- Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Review article
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “LifeSenze WELLMENZ Tablet”, https://compoatlas.com/en/supplements/malaysia/MAL24066105TC-lifesenze-wellmenz-tablet, updated 27 October 2026.